Lantheus (LNTH)
Market Price (12/27/2025): $66.7 | Market Cap: $4.5 BilSector: Health Care | Industry: Health Care Supplies
Lantheus (LNTH)
Market Price (12/27/2025): $66.7Market Cap: $4.5 BilSector: Health CareIndustry: Health Care Supplies
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 23% | Weak multi-year price returns2Y Excs Rtn is -34%, 3Y Excs Rtn is -54% | Expensive valuation multiplesP/EPrice/Earnings or Price/(Net Income) is 27x |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 30%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 25% | Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 11% | Key risksLNTH key risks include [1] intensifying competition and pricing pressures eroding the market position of its flagship product, Show more. |
| Attractive yieldFCF Yield is 8.5% | ||
| Megatrend and thematic driversMegatrends include Precision Medicine, and Biotechnology & Genomics. Themes include Personalized Diagnostics, Targeted Therapies, Show more. |
| Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 23% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 30%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 25% |
| Attractive yieldFCF Yield is 8.5% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Biotechnology & Genomics. Themes include Personalized Diagnostics, Targeted Therapies, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -34%, 3Y Excs Rtn is -54% |
| Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 11% |
| Expensive valuation multiplesP/EPrice/Earnings or Price/(Net Income) is 27x |
| Key risksLNTH key risks include [1] intensifying competition and pricing pressures eroding the market position of its flagship product, Show more. |
Why The Stock Moved
Qualitative Assessment
AI Analysis | Feedback
<b>1. Q3 2025 Financial Results and Outlook</b><br><br>
Lantheus reported third-quarter 2025 worldwide revenue of $384.0 million, surpassing analyst estimates. However, GAAP fully diluted earnings per share (EPS) significantly decreased to $0.41, a 77.1% drop from the prior year, and adjusted fully diluted EPS also declined to $1.27, a 25.3% decrease. Sales of PYLARIFY decreased by 7.4% to $240.6 million, while DEFINITY sales increased by 6.3% to $81.8 million. Despite the mixed earnings performance, the company reaffirmed its full-year 2025 revenue and adjusted EPS guidance, indicating confidence in its future outlook.
<br><br>
<b>2. Leadership Transition</b><br><br>
On November 6, 2025, Lantheus announced a significant leadership transition plan. This included the upcoming retirement of CEO Brian Markison at year-end, the departure of the President, and the appointment of Mary Anne Heino, a former CEO, to the role of Executive Chairperson. The Board of Directors initiated a search for a new CEO.
<br><br>
<b>3. Share Repurchase Program</b><br><br>
In the third quarter of 2025, Lantheus repurchased $100 million of its common stock. This action was part of a new share repurchase program, authorized by the board of directors on August 6, 2025, which allows for repurchases of up to $400 million of common stock through December 31, 2027, replacing a previous program.
<br><br>
<b>4. Strategic Acquisition and Robust Pipeline Updates</b><br><br>
The acquisition of Life Molecular Imaging, completed in July 2025, was highlighted in the Q3 earnings report as a strategic move that immediately expanded Lantheus' near- and long-term growth profile and commercial portfolio. Furthermore, the company announced several significant pipeline advancements, including FDA acceptance of a New Drug Application (NDA) for a new formulation of its piflufolastat F 18 PSMA PET imaging agent, with a PDUFA date set for March 6, 2026. Lantheus also received PDUFA dates for MK-6240, its F 18 tau-targeted PET imaging agent, and LNTH-2501, a Ga 68 PET diagnostic imaging kit.
<br><br>
<b>5. Positive Analyst Sentiment and Price Targets</b><br><br>
Throughout the period from August 2025 to December 2025, multiple Wall Street analysts maintained or upgraded their ratings for Lantheus. The consensus among analysts was generally a "Moderate Buy" or "Strong Buy," with an average price target indicating a potential upside in the stock price. For instance, in December 2025, Truist Securities upgraded Lantheus Holdings to a "Strong Buy" and Mizuho maintained an "Outperform" recommendation.
Show moreStock Movement Drivers
Fundamental Drivers
The 31.8% change in LNTH stock from 9/26/2025 to 12/26/2025 was primarily driven by a 109.0% change in the company's P/E Multiple.| 9262025 | 12262025 | Change | |
|---|---|---|---|
| Stock Price ($) | 50.61 | 66.71 | 31.81% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 1520.65 | 1525.93 | 0.35% |
| Net Income Margin (%) | 17.82% | 10.99% | -38.34% |
| P/E Multiple | 12.80 | 26.75 | 109.03% |
| Shares Outstanding (Mil) | 68.52 | 67.23 | 1.88% |
| Cumulative Contribution | 31.77% |
Market Drivers
9/26/2025 to 12/26/2025| Return | Correlation | |
|---|---|---|
| LNTH | 31.8% | |
| Market (SPY) | 4.3% | 16.7% |
| Sector (XLV) | 15.2% | 37.2% |
Fundamental Drivers
The -18.1% change in LNTH stock from 6/27/2025 to 12/26/2025 was primarily driven by a -33.6% change in the company's Net Income Margin (%).| 6272025 | 12262025 | Change | |
|---|---|---|---|
| Stock Price ($) | 81.49 | 66.71 | -18.14% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 1536.70 | 1525.93 | -0.70% |
| Net Income Margin (%) | 16.55% | 10.99% | -33.60% |
| P/E Multiple | 22.00 | 26.75 | 21.55% |
| Shares Outstanding (Mil) | 68.67 | 67.23 | 2.10% |
| Cumulative Contribution | -18.17% |
Market Drivers
6/27/2025 to 12/26/2025| Return | Correlation | |
|---|---|---|
| LNTH | -18.1% | |
| Market (SPY) | 12.6% | -0.5% |
| Sector (XLV) | 17.0% | 30.2% |
Fundamental Drivers
The -28.5% change in LNTH stock from 12/26/2024 to 12/26/2025 was primarily driven by a -61.5% change in the company's Net Income Margin (%).| 12262024 | 12262025 | Change | |
|---|---|---|---|
| Stock Price ($) | 93.25 | 66.71 | -28.46% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 1496.80 | 1525.93 | 1.95% |
| Net Income Margin (%) | 28.57% | 10.99% | -61.54% |
| P/E Multiple | 15.15 | 26.75 | 76.57% |
| Shares Outstanding (Mil) | 69.46 | 67.23 | 3.22% |
| Cumulative Contribution | -28.54% |
Market Drivers
12/26/2024 to 12/26/2025| Return | Correlation | |
|---|---|---|
| LNTH | -28.5% | |
| Market (SPY) | 15.8% | 16.5% |
| Sector (XLV) | 13.3% | 23.9% |
Fundamental Drivers
The 35.9% change in LNTH stock from 12/27/2022 to 12/26/2025 was primarily driven by a 90.4% change in the company's Total Revenues ($ Mil).| 12272022 | 12262025 | Change | |
|---|---|---|---|
| Stock Price ($) | 49.10 | 66.71 | 35.87% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 801.46 | 1525.93 | 90.39% |
| Net Income Margin (%) | 13.36% | 10.99% | -17.72% |
| P/E Multiple | 31.54 | 26.75 | -15.20% |
| Shares Outstanding (Mil) | 68.76 | 67.23 | 2.22% |
| Cumulative Contribution | 35.80% |
Market Drivers
12/27/2023 to 12/26/2025| Return | Correlation | |
|---|---|---|
| LNTH | 8.5% | |
| Market (SPY) | 48.0% | 13.4% |
| Sector (XLV) | 18.2% | 21.4% |
Price Returns Compared
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| LNTH Return | -34% | 114% | 76% | 22% | 44% | -25% | 225% |
| Peers Return | 16% | 38% | -12% | 21% | 26% | 16% | 150% |
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 18% | 114% |
Monthly Win Rates [3] | |||||||
| LNTH Win Rate | 42% | 75% | 58% | 67% | 67% | 67% | |
| Peers Win Rate | 52% | 65% | 42% | 68% | 57% | 52% | |
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 73% | |
Max Drawdowns [4] | |||||||
| LNTH Max Drawdown | -56% | 0% | -16% | -6% | -18% | -44% | |
| Peers Max Drawdown | -34% | -5% | -26% | -7% | -9% | -23% | |
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | |
[1] Cumulative total returns since the beginning of 2020
[2] Peers: HPQ, HPE, IBM, CSCO, AAPL.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/26/2025 (YTD)
How Low Can It Go
| Event | LNTH | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -44.8% | -25.4% |
| % Gain to Breakeven | 81.3% | 34.1% |
| Time to Breakeven | 94 days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -55.6% | -33.9% |
| % Gain to Breakeven | 125.1% | 51.3% |
| Time to Breakeven | 377 days | 148 days |
| 2018 Correction | ||
| % Loss | -47.8% | -19.8% |
| % Gain to Breakeven | 91.6% | 24.7% |
| Time to Breakeven | 140 days | 120 days |
Compare to HPQ, HPE, IBM, CSCO, AAPL
In The Past
Lantheus's stock fell -44.8% during the 2022 Inflation Shock from a high on 8/25/2022. A -44.8% loss requires a 81.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
AI Analysis | Feedback
Here are 1-2 brief analogies to describe Lantheus (LNTH):
Like a specialized, standalone version of Novartis's radiopharmaceutical business, focused on developing radioactive compounds for both advanced medical imaging and targeted cancer therapies.
Exact Sciences (known for Cologuard), but focused on creating advanced injectable imaging agents that light up cancers for precise diagnosis, particularly prostate cancer.
AI Analysis | Feedback
- PYLARIFY®: An advanced PET imaging agent used for detecting and staging prostate cancer.
- DEFINITY®: An ultrasound enhancing agent that improves visualization of the left ventricular endocardial border in echocardiograms.
- TECHNETIUM 99M Generators: Devices that produce Technetium 99m, a widely used radioisotope for various diagnostic nuclear medicine procedures.
- AZEDRA®: A targeted radiotherapeutic agent for specific rare neuroendocrine tumors.
- XENON-133: A diagnostic radioactive gas primarily used for lung ventilation imaging studies.
AI Analysis | Feedback
Lantheus (symbol: LNTH) primarily sells its products to other companies rather than directly to individuals.
According to its most recent annual report (10-K), Lantheus states that no single customer accounted for more than 10% of its consolidated net revenue in 2023, 2022, or 2021. This indicates a diversified customer base and means that there are no individually "major customer companies" that are required to be disclosed by name in its public filings as exceeding a significant percentage of total revenue.
Therefore, instead of specific named companies that represent a dominant share of revenue, Lantheus's major customers can be described by the following categories of organizations that purchase and utilize its radiopharmaceutical products:
- Hospitals and Health Systems: These are primary institutional customers where Lantheus's diagnostic imaging agents and targeted radiotherapeutics are administered to patients.
- Diagnostic Imaging Centers and Clinics: Specialized outpatient facilities focused on medical imaging, including PET (Positron Emission Tomography) scans, which utilize Lantheus products like PYLARIFY.
- Pharmaceutical Wholesalers and Distributors: These companies serve as intermediaries, purchasing products directly from Lantheus and then distributing them to the aforementioned hospitals, health systems, and imaging centers. Major players in this sector include Cencora (formerly AmerisourceBergen) (Symbol: COR), Cardinal Health (Symbol: CAH), and McKesson Corporation (Symbol: MCK). While these are key direct corporate customers in the supply chain, as noted, no single one represents a "major customer" in terms of exceeding 10% of Lantheus's total revenue.
AI Analysis | Feedback
Jubilant Pharmova Limited (NSE: JUBLPHARMA)
NRG
Australian Nuclear Science and Technology Organisation (ANSTO)
ITM Isotope Technologies Munich SE
AI Analysis | Feedback
Mary Anne Heino, Executive Chairperson and Interim Chief Executive Officer
Mary Anne Heino has served as Executive Chairperson of Lantheus since November 7, 2025, and will lead the company as interim CEO following the retirement of Brian Markison at the end of 2025. She previously held the role of CEO of Lantheus from August 2015 to March 2024, and was also President during part of that period. During her tenure as CEO, she led the acquisition of Progenics and spearheaded the development and commercialization of a leading PSMA-targeted PET imaging agent for prostate cancer. She joined Lantheus in April 2013 as Chief Commercial Officer and was promoted to Chief Operating Officer in March 2015. Prior to Lantheus, Ms. Heino held senior commercial and strategic leadership roles at Angelini Labopharm LLC and Labopharm USA (2007-2012), and Centocor, Inc., a Johnson & Johnson company (2000-2007). She began her professional career in sales and marketing at Janssen Pharmaceutica, another Johnson & Johnson company.
Robert J. Marshall Jr., Chief Financial Officer and Treasurer
Robert J. Marshall Jr. serves as the Chief Financial Officer and Treasurer of Lantheus. He has also served as Chief Financial Officer and Treasurer of Lantheus Medical Imaging.
Daniel Niedzwiecki, Chief Administrative Officer, General Counsel & Corporate Secretary
Daniel Niedzwiecki serves as Chief Administrative Officer, General Counsel, and Corporate Secretary at Lantheus. He was appointed Chief Administrative Officer in March 2023, General Counsel in April 2021, and Corporate Secretary in April 2019.
Amanda Morgan, Chief Commercial Officer
Amanda Morgan serves as the Chief Commercial Officer for Lantheus, a role she returned to after a leave of absence, reporting directly to Mary Anne Heino.
Jean-Claude Provost, Chief Medical Officer
Jean-Claude Provost serves as the Chief Medical Officer at Lantheus.
AI Analysis | Feedback
The key risks to Lantheus's business are primarily centered around its reliance on its flagship product, increasing market competition, and challenges related to recent strategic acquisitions.
- Product Concentration and Intensifying Competition for PYLARIFY: Lantheus's financial health is heavily dependent on PYLARIFY, its prostate cancer imaging agent, which is the main revenue driver. Sales of PYLARIFY have shown signs of slowing due to intensifying price competition in the PSMA PET imaging market. For instance, PYLARIFY sales dropped by 7.4% in Q3 2025, indicating significant market pressure. Analysts have lowered their price targets on Lantheus due to "Pylarify pricing pressures" and "competitive share loss risks". The entry of generic competitors post-2026 could further exacerbate competition, impacting market share and revenue. There is also an ongoing class action lawsuit alleging that Lantheus misled investors by not fully disclosing the pricing risks for PYLARIFY, which reportedly led to erosion of its market position.
- Acquisition Integration and Pipeline Development Challenges: Lantheus has undertaken strategic acquisitions, such as Evergreen Theragnostics and Life Molecular Imaging (which includes the Alzheimer's diagnostic Neuraceq®), to diversify its revenue streams. However, integrating these new businesses and their associated costs is expected to strain resources and management focus in the short term. Such acquisitions inherently carry operational and financial risks, including the potential for reduced financial resources, the incurrence of substantial debt, and difficulties in effectively combining operations and retaining key personnel. While these diversification efforts are crucial, they are projected to yield only low-single-digit earnings per share accretion in the near term, with integration and potential dilution risks remaining.
- Leadership Transition: The impending retirement of Lantheus's CEO at the end of 2025 introduces an element of uncertainty. This leadership change comes at a critical juncture for the company, as it navigates competitive pressures and seeks to integrate new acquisitions for future growth.
AI Analysis | Feedback
Emergence of next-generation alpha-emitting radioligand therapies (RLTs) for prostate cancer.
AI Analysis | Feedback
Lantheus (symbol: LNTH) has several key products and services with identifiable addressable markets:
- PYLARIFY (piflufolastat F 18): This is a PET radiotracer used for imaging prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer.
- The U.S. addressable market for PYLARIFY is estimated at $1.6 billion.
- The total addressable market for PSMA PET imaging agents for prostate cancer in the U.S. is projected to be over $2.5 billion in 2025, increasing from over $2 billion in 2024, and could surpass $3.5 billion by the end of the decade.
- The global PSMA PET Imaging Market reached US$1.5 billion in 2022 and is expected to reach US$2 billion by 2030.
- The U.S. prostate cancer nuclear medicine diagnostics market size was estimated at USD 75.06 million in 2022 and is expected to reach USD 153.97 million by 2030.
- The current market potential for PSMA PET imaging agents in the U.S. for 2024 could be about 445,000 scans, with a total addressable market potentially exceeding 700,000 annual scans by 2029.
- DEFINITY (Perflutren Lipid Microsphere) Injectable Suspension: This is an ultrasound enhancing agent primarily used in echocardiography procedures.
- Lantheus holds over 80% of the U.S. market share for ultrasound enhancing agents in echocardiography procedures as of the end of 2023.
- The global contrast-enhanced ultrasound market is projected to reach USD 2.1 billion by 2028, growing from USD 1.6 billion in 2023.
- TechneLite (Technetium Tc 99m Generator): This product provides Technetium (Tc99m), a radioactive isotope essential for preparing various nuclear imaging agents.
- Technetium-99m (Tc-99m) is used in over 40 million diagnostic procedures annually globally.
- The global radiopharmaceuticals market, which includes TechneLite, was valued at US$ 6.8 billion in 2024 and is expected to reach US$ 13.4 billion by 2033.
- The U.S. radiopharmaceuticals market was valued at USD 2.21 billion in 2024 and is estimated to reach USD 2.36 billion by 2033.
- Alzheimer's Disease Diagnostics (including Neuraceq, MK-6240, and NAV-4694): These products are PET imaging agents for detecting beta-amyloid plaques and tau pathology in patients evaluated for Alzheimer's disease.
- Lantheus anticipates a total addressable market size for Alzheimer's disease diagnostics of $1.5 billion globally in 2030 and $2.5 billion globally by mid-2030.
- The U.S. Alzheimer's disease radiodiagnostic market is considered to have significant growth potential.
- PNT2003: This is a therapeutic candidate for neuroendocrine tumors.
- The addressable U.S. market for PNT2003 is approximately $1 billion and is expected to expand to over $5 billion by 2029.
- The total addressable market for somatostatin NET PET diagnostics is estimated at $200 million or 50,000 patients per year.
- AZEDRA (iobenguane I-131): This radiopharmaceutical was used for the treatment of pheochromocytoma and paraganglioma. Lantheus announced its discontinuation in August 2023 due to insufficient uptake and high manufacturing costs.
AI Analysis | Feedback
Lantheus (LNTH) is poised for future revenue growth over the next 2-3 years, driven by several key factors:
- Continued Growth and Market Expansion of PYLARIFY: PYLARIFY, a leading PSMA PET imaging agent for prostate cancer, achieved blockbuster status in 2024 with over $1 billion in sales and is expected to continue its growth trajectory. The addressable market for PSMA PET imaging is projected to expand significantly, reaching an estimated $2.5+ billion in 2025 and potentially exceeding $3.5 billion by the end of the decade. This growth is fueled by increasing patient volumes, the conversion from conventional imaging methods, broader adoption among healthcare providers, and strategic partnerships. Furthermore, a new formulation of PYLARIFY is expected to increase batch size by approximately 50%, allowing Lantheus to serve significantly more patients.
- Sustained Performance and Market Leadership of DEFINITY: DEFINITY, Lantheus's high-resolution echocardiogram enhancement agent, continues to demonstrate robust performance and maintain its strong market leadership in the ultrasound-enhancing agent market. Its consistent growth is driven by ongoing market expansion and opportunistic sales, partly due to competitor supply challenges.
- Expansion into Alzheimer's Diagnostics through Strategic Acquisitions and Pipeline: Lantheus is diversifying its portfolio by entering the Alzheimer's diagnostics market. The acquisition of Life Molecular Imaging brings Neuraceq, an approved radiodiagnostic for Alzheimer's disease, and enhances R&D capabilities in this area. Additionally, Lantheus has pipeline candidates like MK-6240 and NAV-4694, which are radio diagnostics for Alzheimer's disease, with regulatory submissions anticipated in 2025 and 2026, respectively.
- Entry into Neuroendocrine Tumors and Radioligand Therapy Manufacturing via Acquisitions: The acquisition of Evergreen Theragnostics adds OCTEVY, a registrational-stage PET imaging agent targeting neuroendocrine tumors, which complements Lantheus's therapeutic candidate PNT2003. This acquisition also provides Lantheus with radioligand therapy manufacturing infrastructure, including a revenue-generating contract development and manufacturing organization (CDMO) business, further diversifying its revenue streams.
- Favorable Regulatory Environment and Improved Reimbursement: A significant driver for future growth is the supportive regulatory environment, particularly the Centers for Medicare & Medicaid Services (CMS) decision to implement separate payment for diagnostic radiopharmaceuticals starting in 2025. This change is expected to improve patient access and foster innovation for products like PYLARIFY.
AI Analysis | Feedback
Share Repurchases
- In November 2024, Lantheus's board authorized a share repurchase program of up to $250 million.
- This program was subsequently replaced in August 2025 with a new authorization for up to $400 million in share repurchases, valid through December 31, 2027.
- Lantheus repurchased $100 million of its common stock in the third quarter of 2025, following approximately $100 million in repurchases during 2024.
Outbound Investments
- In July 2025, Lantheus completed the acquisition of Life Molecular Imaging for approximately $309 million (net of cash acquired), which expanded its nuclear medicine commercial portfolio.
- The company acquired Evergreen Theragnostics, Inc. for $276.4 million in April 2025, enhancing its radioligand manufacturing capabilities.
- Lantheus made a strategic investment of approximately A$7.6 million (US$5 million) in Radiopharm Theranostics in October 2025 as part of a private placement.
Capital Expenditures
- Capital expenditures were $10.6 million in the third quarter of 2025 and $8.0 million in the second quarter of 2025.
- Annual capital expenditures were approximately $35.3 million in 2024, $27.3 million in 2023, and $15.8 million in 2022.
- For the years 2021 and 2020, capital expenditures were approximately $11.2 million and $8.0 million, respectively.
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to LNTH. For more, see Trefis Trade Ideas.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 21.4% | 21.4% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -7.4% | -7.4% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 18.0% | 18.0% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 3.9% | 3.9% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 12.2% | 12.2% | -5.1% |
| 08312025 | LNTH | Lantheus | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | 21.5% | 21.5% | -8.7% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for Lantheus
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 72.44 |
| Mkt Cap | 158.8 |
| Rev LTM | 56,496 |
| Op Inc LTM | 7,584 |
| FCF LTM | 7,327 |
| FCF 3Y Avg | 7,366 |
| CFO LTM | 8,590 |
| CFO 3Y Avg | 8,697 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 5.2% |
| Rev Chg 3Y Avg | 3.2% |
| Rev Chg Q | 8.3% |
| QoQ Delta Rev Chg LTM | 2.0% |
| Op Mgn LTM | 20.1% |
| Op Mgn 3Y Avg | 18.1% |
| QoQ Delta Op Mgn LTM | -0.1% |
| CFO/Rev LTM | 22.2% |
| CFO/Rev 3Y Avg | 23.8% |
| FCF/Rev LTM | 20.1% |
| FCF/Rev 3Y Avg | 21.6% |
FDA Approved Drugs Data
Expand for More| Post-Approval Fwd Returns | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| FDA App # | Brand Name | Generic Name | Dosage Form | FDA Approval | 3M Rtn | 6M Rtn | 1Y Rtn | 2Y Rtn | Total Rtn |
| NDA021711 | ABLAVAR | gadofosveset trisodium | solution | 12222008 | |||||
Segment Financials
Revenue by Segment| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| PYLARIFY | 851 | 527 | 43 | ||
| DEFINITY | 280 | 245 | 233 | 196 | 218 |
| TechneLite | 87 | 89 | 91 | 85 | 87 |
| Strategic partnerships and other revenue | 52 | 47 | 25 | 12 | |
| Other precision diagnostics | 23 | 23 | 27 | 37 | |
| Other radiopharmaceutical oncology | 3 | 4 | 5 | 10 | |
| Other nuclear | 60 | ||||
| Rebates and allowances | -17 | ||||
| Total | 1,296 | 935 | 425 | 339 | 347 |
Price Behavior
| Market Price | $66.71 | |
| Market Cap ($ Bil) | 4.5 | |
| First Trading Date | 06/25/2015 | |
| Distance from 52W High | -39.4% | |
| 50 Days | 200 Days | |
| DMA Price | $58.70 | $71.41 |
| DMA Trend | down | up |
| Distance from DMA | 13.6% | -6.6% |
| 3M | 1YR | |
| Volatility | 37.2% | 56.1% |
| Downside Capture | 24.43 | 48.82 |
| Upside Capture | 152.46 | 8.19 |
| Correlation (SPY) | 16.1% | 16.4% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.92 | 0.63 | 0.48 | 0.13 | 0.47 | 0.59 |
| Up Beta | 0.93 | 1.55 | 1.87 | 0.49 | 0.66 | 0.56 |
| Down Beta | 0.52 | -0.03 | -0.18 | 0.34 | 0.49 | 0.55 |
| Up Capture | 145% | 114% | 50% | -34% | -1% | 20% |
| Bmk +ve Days | 13 | 26 | 39 | 74 | 142 | 427 |
| Stock +ve Days | 10 | 21 | 31 | 64 | 127 | 384 |
| Down Capture | 72% | 31% | 29% | 24% | 56% | 86% |
| Bmk -ve Days | 7 | 16 | 24 | 52 | 107 | 323 |
| Stock -ve Days | 10 | 21 | 32 | 61 | 121 | 364 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Comparison of LNTH With Other Asset Classes (Last 1Y) | |||||||
|---|---|---|---|---|---|---|---|
| LNTH | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | -25.3% | 15.1% | 17.8% | 72.1% | 8.6% | 4.4% | -8.3% |
| Annualized Volatility | 55.9% | 17.2% | 19.4% | 19.3% | 15.2% | 17.0% | 35.0% |
| Sharpe Ratio | -0.29 | 0.65 | 0.72 | 2.70 | 0.34 | 0.09 | -0.08 |
| Correlation With Other Assets | 24.1% | 16.5% | 4.9% | 3.7% | 20.1% | -2.0% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Comparison of LNTH With Other Asset Classes (Last 5Y) | |||||||
|---|---|---|---|---|---|---|---|
| LNTH | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | 35.3% | 8.4% | 14.7% | 18.7% | 11.5% | 4.6% | 30.8% |
| Annualized Volatility | 57.5% | 14.5% | 17.1% | 15.5% | 18.7% | 18.9% | 48.7% |
| Sharpe Ratio | 0.75 | 0.40 | 0.70 | 0.97 | 0.50 | 0.16 | 0.57 |
| Correlation With Other Assets | 25.3% | 26.6% | 6.5% | 9.4% | 27.2% | 8.1% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Comparison of LNTH With Other Asset Classes (Last 10Y) | |||||||
|---|---|---|---|---|---|---|---|
| LNTH | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | 34.1% | 9.9% | 14.8% | 15.3% | 7.0% | 5.3% | 69.2% |
| Annualized Volatility | 62.7% | 16.6% | 18.0% | 14.7% | 17.6% | 20.8% | 55.8% |
| Sharpe Ratio | 0.73 | 0.49 | 0.71 | 0.86 | 0.32 | 0.22 | 0.90 |
| Correlation With Other Assets | 29.9% | 31.7% | 2.6% | 13.9% | 29.1% | 7.5% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/6/2025 | -6.2% | -4.8% | 8.8% |
| 8/6/2025 | -28.6% | -25.8% | -25.9% |
| 5/7/2025 | -23.2% | -24.7% | -23.4% |
| 1/28/2025 | -7.3% | -8.9% | -5.1% |
| 11/6/2024 | -20.7% | -25.9% | -22.3% |
| 7/31/2024 | -4.5% | -10.6% | -0.1% |
| 5/2/2024 | 16.0% | 10.6% | 21.4% |
| 2/22/2024 | 14.7% | 15.3% | 3.5% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 8 | 9 | 11 |
| # Negative | 13 | 12 | 10 |
| Median Positive | 14.8% | 15.3% | 8.8% |
| Median Negative | -6.7% | -13.2% | -16.8% |
| Max Positive | 39.1% | 81.6% | 76.5% |
| Max Negative | -28.6% | -25.9% | -27.2% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 9302025 | 11062025 | 10-Q 9/30/2025 |
| 6302025 | 8062025 | 10-Q 6/30/2025 |
| 3312025 | 5072025 | 10-Q 3/31/2025 |
| 12312024 | 2262025 | 10-K 12/31/2024 |
| 9302024 | 11062024 | 10-Q 9/30/2024 |
| 6302024 | 7312024 | 10-Q 6/30/2024 |
| 3312024 | 5022024 | 10-Q 3/31/2024 |
| 12312023 | 2222024 | 10-K 12/31/2023 |
| 9302023 | 11022023 | 10-Q 9/30/2023 |
| 6302023 | 8032023 | 10-Q 6/30/2023 |
| 3312023 | 5042023 | 10-Q 3/31/2023 |
| 12312022 | 2232023 | 10-K 12/31/2022 |
| 9302022 | 11032022 | 10-Q 9/30/2022 |
| 6302022 | 8042022 | 10-Q 6/30/2022 |
| 3312022 | 4292022 | 10-Q 3/31/2022 |
| 12312021 | 2242022 | 10-K 12/31/2021 |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.